Verséa

What Verséa does

Verséa Health, Inc. is a privately held Tampa, Florida-based life sciences company founded in 2018 that operates four business divisions—Diagnostics, Ophthalmics, Discovery, and Biologics—providing point-of-care diagnostic products, ophthalmic therapeutics, regenerative medicine, and drug discovery platforms. Its Diagnostics division sells professional point-of-care rapid tests and OTC consumer products including the Party Safe Fentanyl ID Test ($19.99 for 5 strips) and Empowered Choice emergency contraceptive. Its Ophthalmics division holds exclusive U.S. commercialization rights for BIOVANCE amniotic membrane products from Celularity and exclusive global rights to AXIM Biotechnologies' tear-based diagnostic portfolio (T-POC platform measuring IgE, Lactoferrin, and MMP-9 biomarkers in 0.5 microliters of tears with results in under 10 minutes). Its Discovery division operates the proprietary VCX™ high-throughput cellular screening platform for drug discovery and mescreen™ for mitochondrial efficiency assessment. The Biologics division is building a regenerative medicine portfolio for spine surgery, orthopedics, trauma, podiatry, and interventional pain.

The company makes money through a multi-channel commercial model combining physician-directed direct sales, value-added distribution partnerships (3EO Health, Acon Laboratories, Advin BioTech), retail pharmacy partnerships (including 86 Pearle Vision stores via the West Point Optical Group agreement), and direct-to-consumer e-commerce including Amazon marketplace. Pricing spans unit-based OTC pricing, quote-based professional diagnostics on multi-year contracts, and a stated positioning as a more affordable alternative to Plan B One Step. Key customers include urgent care centers, primary care practices, pediatricians, functional medicine practitioners, independent pharmacies, eye care providers, and consumer end-buyers. The company is founder-led by CEO Sean Fetcho, with President Rob Sambursky, MD (a corneal specialist and former founder/CEO of RPS Diagnostics and Lumos Diagnostics) leading the ophthalmic expansion since August 2022. Headcount stands at approximately 55, with plans to add 40 more jobs over the next 2-3 years, and CEO Fetcho has publicly cited reaching $50 million in sales as a milestone (contextually attributed to 2021).

Verséa's strategic posture emphasizes partnership-driven exclusivity rather than fully internal product development: BIOVANCE, AXIM diagnostics, and iRemedy e-commerce are all sourced or co-built with external partners. Operational maturity is signaled by ISO 9001 certification achieved across all three original business units in June 2024, a 14,000+ square foot Tampa facility consolidated in May 2023, and a 25-physician scientific advisory board. The company maintains four wholly-owned operating subsidiaries and one joint venture (with iRemedy), and has not disclosed any external institutional funding rounds, suggesting bootstrap or organic growth funding.

Name

Verséa

Legal name

Verséa Health, Inc.

Website

https://versea.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Verséa Health, Inc. is a privately held Tampa-based life sciences company operating four divisions—Diagnostics, Ophthalmics, Discovery, and Biologics—providing point-of-care diagnostics, ophthalmic therapeutics, regenerative medicine, and proprietary drug discovery platforms to healthcare providers and consumers via exclusive partnerships and multi-channel distribution.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics and Medical Devices

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)

akta.pro secondary industries

Toxicology & Therapeutic Drug Monitoring Laboratories (HLAFAMAF), Women’s Health & Fertility Therapeutics (Digital) (HLACANAK)

Keywords

• Point-of-care diagnostics
• Ophthalmic therapeutics
• Tear-based diagnostics
• Mitochondrial testing
• Consumer health products

Headquarters

HQ city

Tampa

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Professional Diagnostics Revenue: Revenue from professional point-of-care diagnostic products sold to healthcare providers including urgent care centers, primary care practices, and independent pharmacies through direct sales and distribution partnerships
2. OTC Consumer Diagnostics Revenue: Revenue from over-the-counter consumer diagnostic products including Party Safe Fentanyl ID Test sold direct-to-consumer via e-commerce
3. Ophthalmics - BIOVANCE Products: Revenue from ophthalmic therapeutic products (BIOVANCE amniotic membrane products) and tear-based diagnostic platforms through exclusive commercialization agreements and distribution partnerships
4. Discovery - Research Validation Services: Revenue from research validation services using proprietary VCX™ and mescreen™ platforms for drug discovery and mitochondrial assessment
5. OTC Consumer Health - Emergency Contraception: Revenue from Empowered Choice emergency contraception product sold direct-to-consumer as a more affordable alternative to Plan B One Step

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Verséa develops, manufactures, and commercializes point-of-care professional diagnostic tests, consumer OTC diagnostic and self-care products (fentanyl detection strips, emergency contraception, at-home lab tests), and ophthalmic therapeutics and tear-based diagnostics (BIOVANCE amniotic membrane allografts, T-POC quantitative testing platform, AXIM biomarker tests). Through its Discovery division it offers proprietary drug discovery and mitochondrial assessment services using the VCX™ and mescreen™ platforms.

Differentiator

Problem solved

Functional benefit

Brands

• Verséa Diagnostics: Point-of-care professional diagnostics, in-office lab services, and consumer OTC diagnostics
• Verséa Ophthalmics
• Verséa Discovery
• Verséa Easy Lab
• Party Safe
• Empowered Choice
• T-POC
• VCX Discovery Platform
• mescreen

Products and services

• BIOVANCE and BIOVANCE 3L Ocular Single-layer and three-layer amniotic membrane allografts commercialized exclusively in the U.S. by Verséa Ophthalmics under license from Celularity, indicated for ocular surface disease treatment and ocular surgical applications and distributed to ophthalmic surgeons and 86 Pearle Vision locations via West Point Optical Group.
• T-POC Quantitative Testing Platform Tear-based point-of-care quantitative diagnostic platform with the TOTAL IgE Immunoassay Kit and Lateral Flow Readers, sold to eye-care providers for diagnosing and managing ocular surface disease; subsequent kits include LACTOFERRIN for aqueous deficient dry eye disease.
• AXIM Ophthalmic Diagnostics Portfolio Exclusive global AXIM tear-based point-of-care diagnostics (Ocular IgE test, Lactoferrin test, and future MMP-9 test) with quantitative results in under 10 minutes from 0.5 microliters of tears, commercialized worldwide by Verséa Ophthalmics.
• Party Safe Fentanyl ID Test Over-the-counter fentanyl detection test strip kit (5 strips, $19.99) for consumer drug-checking, sold at U.S. retail locations and via Amazon, manufactured for Verséa by a U.S. supplier serving law enforcement and healthcare providers.
• Empowered Choice Emergency Contraceptive FDA-approved 1.5 mg Levonorgestrel emergency contraceptive tablet sold over-the-counter as a more affordable alternative to Plan B One Step, distributed via convenience stores, adult sexual health retailers, specialty retailers, and Amazon.com.
• Verséa Easy Lab At-Home OTC Diagnostic Tests Direct-access rapid at-home OTC diagnostic test product line sold by the Verséa Health division to consumers via e-commerce, supporting physician office laboratory and home health use.
• mescreen Personalized Mitochondrial Efficiency Test Proprietary personalized mitochondrial efficiency test within the Discovery division, leveraging the mescreen platform to assess mitochondrial function for health and research applications.
• mescreen Research Validator Proprietary compound assessment platform within the Verséa Discovery division that uses mitochondrial function and dynamics to generate data for evaluating the therapeutic potential of compounds, offered to pharmaceutical and research customers.
• VCX Discovery Platform Proprietary high-throughput cellular screening platform within the Verséa Discovery division used for drug discovery applications and personalized medicine research.

Named customers5 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Eight partnerships are on record, tiered core, flagship and minor.

• West Point Optical Group, LLCcoreChannel Partner/ Reseller/ Distributor · 3 April 2024Partnership supply agreement for BIOVANCE ophthalmic products. West Point Optical Group serves as a distribution partner for amniotic membrane products in the ophthalmic market.
• Celularity Inc.flagshipStrategic or Co-development Partner · 27 July 2023Exclusive U.S. commercialization agreement for BIOVANCE products. This is a key strategic partnership providing Verséa exclusive rights to commercialize BIOVANCE amniotic membrane products in the United States market.
• iRemedy Healthcare CompaniescoreStrategic or Co-development Partner · 28 June 2023Strategic joint venture partnership focused on healthcare distribution and market access. Combines Verséa's diagnostic products with iRemedy's healthcare distribution capabilities.
• Doc JohnsonminorChannel Partner/ Reseller/ Distributor · 15 June 2023Wellness center partnership for consumer health product distribution. Doc Johnson's wellness centers distribute Verséa's consumer health products including emergency contraception.
• AXIM BiotechnologiesflagshipStrategic or Co-development Partner · 19 September 2022Exclusive global commercialization agreement for ophthalmic diagnostics. Grants Verséa exclusive worldwide rights to commercialize AXIM's ophthalmic diagnostic technologies and products.
• Intertek Group plcminorImplementation/ SI/ Consulting PartnerISO 9001 certification audit partner. Intertek conducted the quality management system certification audit for Verséa's operations.
• AME Quality & Compliance Solutions, LLCminorImplementation/ SI/ Consulting PartnerQuality management system implementation partner. AME Quality & Compliance Solutions assisted Verséa with implementing and establishing their quality management system.
• Distribution Partner NetworkcoreChannel Partner/ Reseller/ DistributorNetwork of value-added distribution partners including 3EO Health, Acon Laboratories, Advin BioTech, and other major distributors for professional diagnostic products across healthcare provider markets.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Bausch + Lomb: Global ophthalmic pharmaceuticals and devices company with presence in ocular surface disease therapeutics. Broad incumbent adjacent to Verséa Ophthalmics' BIOVANCE franchise and Pearle Vision distribution model.
• Hologic: Women's health and diagnostics leader with POC molecular and rapid testing products. Comparable to Verséa Diagnostics' physician office lab strategy and the women's health positioning of Empowered Choice emergency contraception.
• Bio-Rad Laboratories: Clinical diagnostics and life science research company with POC, QC, and specialty testing products. Comparable as a broad incumbent serving physician office and reference lab channels where Verséa Diagnostics sells.
• Abbott Point of Care: Division of Abbott operating the i-STAT and BinaxNOW platforms in physician offices, urgent care, and hospitals. Broad incumbent competitor to Verséa's professional POC franchise across most of the same end customers.
• QuidelOrtho: Large-scale diagnostics company spanning immunoassays, molecular diagnostics, and rapid POC tests (Sofia, QuickVue). A broad incumbent whose professional POC menu competes directly with Verséa Diagnostics in urgent care and primary care channels.

Direct peers

• ACON Laboratories: Global manufacturer of rapid diagnostic tests, including OTC and professional POC products for pregnancy, infectious disease, and drugs of abuse. Direct peer to Verséa Diagnostics' rapid test business and an existing Verséa distribution partner.
• OraSure Technologies: Specialty diagnostics and OTC sample collection company with products including at-home infectious disease and drug detection tests. Directly comparable to Verséa Diagnostics' OTC consumer portfolio (Easy Lab, Party Safe) and physician office lab offerings.
• Premier Biotech: Specialty manufacturer of drug-of-abuse and fentanyl detection test strips sold into clinical, workplace, and harm-reduction channels. Closely comparable to Verséa's Party Safe Fentanyl ID Test product line.
• Lumos Diagnostics: Rapid point-of-care diagnostics company focused on infectious disease and inflammatory markers. Highly comparable to Verséa Diagnostics: same POC business model, overlapping products (febrile respiratory tests), and — most notably — Rob Sambursky, MD, the current Verséa President, was founder and former CEO of Lumos.

Emerging players

• AXIM Biotechnologies: Developer of the tear-based IgE, Lactoferrin, and MMP-9 diagnostic assays licensed exclusively to Verséa. Tangentially comparable as a peer/partner — a small-cap emerging player whose platform underpins Verséa Ophthalmics' T-POC franchise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/verseahealth

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Verséa